Methylene Blue Cuts ICU Stay and Organ Damage After Cardiac Surgery Shock

Cardiopulmonary bypass (CPB) triggers systemic inflammation that can spiral into vasoplegic syndrome—a distributive shock state defined by profound hypotension, low systemic vascular resistance, and preserved or elevated cardiac output despite high-dose vasopressors. Its incidence ranges from 5% to 44% depending on case complexity, and it is expected to rise as cardiac surgery takes on sicker patients. Standard treatment with norepinephrine, vasopressin, and phenylephrine can fail or cause ischemic complications at high doses, motivating interest in adjunct therapies.

Methylene blue inhibits soluble guanylate cyclase (sGC), the enzyme that converts GTP to cyclic GMP in response to nitric oxide. By blocking this pathway, MB prevents myosin light-chain dephosphorylation and the smooth-muscle relaxation that underlies pathological vasodilation. This mechanism makes it a mechanistically rational rescue agent for refractory vasoplegia.

Researchers at Friedrich-Alexander-University Erlangen reviewed 2,753 consecutive CPB cases over two years. Of these, 200 (7.2%) met a strict hemodynamic definition of norepinephrine-refractory vasoplegia (MAP <60 mmHg, CI ≥2.5 L/min/m², CVP <8 mmHg, PCWP <10 mmHg, SVR <600 dyne·s·cm⁻⁵ on ≥0.5 µg/kg/min norepinephrine). After excluding active endocarditis and major bleeding cases, 84 patients received MB (2 mg/kg IV bolus then 0.5 mg/kg/hr for 12 hours) within 24 hours postoperatively; 116 received standard vasopressor care only. Groups were broadly comparable in EuroSCORE and APACHE II severity, though MB patients were about five years younger and more likely to have received a ventricular assist device.

Key results strongly favored MB across secondary endpoints. ICU stay was 9±8 days in the MB group versus 16±6.9 days in controls (p<0.001). Serum lactate at 24 hours—a proxy for global tissue perfusion—was 1.8±1.2 vs. 4.0±1.8 mmol/L (p<0.001). Postoperative hemodialysis occurred in 20% of MB patients versus 40% of controls (p<0.05), and the 24-hour norepinephrine requirement was lower (1.5±1.2 vs. 2.8±2.0 mg/hr, p<0.05). SVR rose sharply after MB administration but by 48 hours both groups converged, suggesting MB provides a critical early hemodynamic bridge rather than sustained vasoconstriction. In-hospital mortality was 38% (MB) versus 43% (controls)—a clinically meaningful but statistically non-significant difference, likely reflecting insufficient power.

One notable adverse event occurred: a patient developed acute pulmonary hypertensive crisis within 10 minutes of MB infusion, with mean PAP rising from 12 to 50 mmHg, requiring immediate drug cessation. PAP normalized over 48 hours. This underscores the need for close hemodynamic monitoring during MB administration. Overall, the findings support early MB use as a morbidity-reducing adjunct in post-CPB vasoplegia, with potential mortality benefit warranting confirmation in a prospective randomized trial.